Compare BAX & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAX | TECH |
|---|---|---|
| Founded | 1931 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 10.2B |
| IPO Year | 1994 | 1995 |
| Metric | BAX | TECH |
|---|---|---|
| Price | $17.96 | $51.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $22.13 | ★ $73.09 |
| AVG Volume (30 Days) | ★ 9.4M | 2.1M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | 0.22% | ★ 0.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.49 |
| Revenue | ★ $11,244,000,000.00 | $1,219,635,000.00 |
| Revenue This Year | $1.90 | $2.49 |
| Revenue Next Year | $2.09 | $6.40 |
| P/E Ratio | ★ N/A | $109.66 |
| Revenue Growth | ★ 5.72 | 5.23 |
| 52 Week Low | $17.07 | $46.02 |
| 52 Week High | $35.03 | $72.16 |
| Indicator | BAX | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 37.42 | 32.09 |
| Support Level | $17.69 | $48.93 |
| Resistance Level | $19.31 | $54.08 |
| Average True Range (ATR) | 0.72 | 2.46 |
| MACD | -0.29 | -0.38 |
| Stochastic Oscillator | 17.89 | 20.31 |
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.